ASAH3 inhibitors encompass various compounds that influence the metabolism of sphingolipids, particularly the levels of ceramide and sphingosine, which are critical to the functional activity of ASAH3. Ceranib-2 and Carmofur work by directly inhibiting acid ceramidase, which results in increased ceramide levels within the cell. This accumulation of ceramide acts as a negative regulator for ASAH3, potentially reducing its hydrolytic activity on ceramide, as ASAH3 functions to convert ceramide to sphingosine. Similarly, compounds like desipramine inhibit acid ceramidase, leading to increased levels of dihydroceramides and ceramides, respectively. Both dihydroceramides and ceramides are substrates for ASAH3, and their elevated levels can lead to competitive inhibition of ASAH3, reducing its activity. Zoledronic acid and Tipifarnib disrupt farnesyltransferase and farnesyl pyrophosphate synthase, respectively, which indirectly affects ceramide metabolism. The alterations in cellular homeostasis and ceramide metabolism due to these disruptions can lead to a downregulation of ASAH3 activity, as the enzyme's functional milieu is compromised.
Other compounds, such as Safingol, inhibit sphingosine kinases and consequently raise sphingosine levels. This results in a competitive scenario where sphingosine, rather than ceramide, becomes more available for ceramidases, potentially inhibiting ASAH3 by reducing its interaction with ceramide. Myriocin and PDMP target steps in the sphingolipid synthesis pathway, with Myriocin inhibiting serine palmitoyltransferase and PDMP inhibiting glucosylceramide synthase. These actions culminate in decreased synthesis of ceramides, and the resulting lower ceramide levels can lead to a compensatory downregulation of ASAH3 activity, as the enzyme's substrate becomes scarce. C2-ceramide, a synthetic ceramide analog, competes with natural ceramide for the active site of ceramidases including ASAH3, which can result in the functional inhibition of ASAH3 as it is unable to interact efficiently with its natural substrate.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ceranib-2 | 1402830-75-4 | sc-507503 | 10 mg | $173.00 | ||
Ceranib-2 is an inhibitor of acid ceramidase, an enzyme that hydrolyzes ceramide into sphingosine and fatty acid. By inhibiting acid ceramidase, Ceranib-2 increases ceramide levels in cells. Given that ASAH3 is involved in the hydrolysis of ceramide, elevated ceramide levels can feedback-inhibit the activity of ASAH3. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $200.00 $680.00 | 18 | |
Fumonisin B1 is an inhibitor of ceramide synthase. Inhibition of ceramide synthase leads to reduced synthesis of ceramide. This reduction in ceramide levels can result in a compensatory downregulation of ASAH3 activity due to a decrease in its substrate availability. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid is a bisphosphonate that inhibits farnesyl pyrophosphate synthase, leading to the accumulation of isopentenyl pyrophosphate, which can inhibit acid ceramidase. The inhibition of acid ceramidase affects ceramide metabolism, potentially reducing ASAH3 activity due to the altered ceramide/sphingosine ratio. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Tipifarnib is a farnesyltransferase inhibitor that leads to the accumulation of unfarnesylated proteins, affecting multiple signaling pathways. This can indirectly influence ceramide metabolism and potentially result in the downregulation of ASAH3 activity due to disrupted cellular homeostasis. | ||||||
Myriocin (ISP-1) | 35891-70-4 | sc-201397 | 10 mg | $150.00 | 8 | |
Myriocin is a potent inhibitor of serine palmitoyltransferase, the initial step in sphingolipid synthesis. Reduced sphingolipid synthesis can lead to lower levels of downstream metabolites, including ceramides, subsequently inhibiting ASAH3 by limiting its substrate availability. | ||||||
C2 Ceramide | 3102-57-6 | sc-201375 sc-201375A | 5 mg 25 mg | $124.00 $460.00 | 12 | |
C2-ceramide is a synthetic analog of ceramide that acts as a cell-permeable ceramide. It can inhibit ceramidases, including ASAH3, by competing with natural ceramide, thereby inhibiting ASAH3 activity by reducing its ability to interact with its natural substrates. | ||||||